137 related articles for article (PubMed ID: 20420190)
1. Induction of DNA breakage in U937 cells by oxazaphosphorines.
Mazur L; Opydo-Chanek M; Stojak M; Baran J; Niemeyer U
Folia Biol (Krakow); 2010; 58(1-2):15-20. PubMed ID: 20420190
[TBL] [Abstract][Full Text] [Related]
2. In vitro cytotoxicity testing of new generation oxazaphosphorines against human histiocytic lymphoma cells.
Opydo-Chanek M; Mazur L; Stojak M
Indian J Exp Biol; 2013 Aug; 51(8):615-22. PubMed ID: 24228385
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of glufosfamide in childhood acute leukemia.
Styczynski J; Wysocki M; Kurylak A; Juraszewska E; Malinowska I; Stanczak E; Płoszynska A; Stefaniak J; Mazur B; Szczepanski T; Ras M
Anticancer Res; 2002; 22(1A):247-50. PubMed ID: 12017297
[TBL] [Abstract][Full Text] [Related]
4. Glufosfamide as a new oxazaphosphorine anticancer agent.
Mazur L; Opydo-Chanek M; Stojak M
Anticancer Drugs; 2011 Jul; 22(6):488-93. PubMed ID: 21427562
[TBL] [Abstract][Full Text] [Related]
5. In vitro effects of new generation oxazaphosphorines on human promyelocytic leukemia cells.
Mazur L; Opydo-Chanek M; Stojak M; Niemeyer U
Folia Biol (Krakow); 2013; 61(1-2):31-40. PubMed ID: 23767290
[TBL] [Abstract][Full Text] [Related]
6. [Perfect drug targeting. Glufosfamide a new derivative].
Holzgrabe U
Pharm Unserer Zeit; 2006; 35(2):158-9. PubMed ID: 16583570
[No Abstract] [Full Text] [Related]
7. In vitro activity of oxazaphosphorines in childhood acute leukemia: preliminary report.
Styczyński J; Wysocki M; Debski R; Balwierz W; Rokicka-Milewska R; Matysiak M; Balcerska A; Kowalczyk J; Wachowiak J; Sońta-Jakimczyk D; Chybicka A
Acta Biochim Pol; 2002; 49(1):221-5. PubMed ID: 12136944
[TBL] [Abstract][Full Text] [Related]
8. Induction of DNA breaks and apoptosis in crosslink-hypersensitive V79 cells by the cytostatic drug beta-D-glucosyl-ifosfamide mustard.
Becker R; Ritter A; Eichhorn U; Lips J; Bertram B; Wiessler M; Zdzienicka MZ; Kaina B
Br J Cancer; 2002 Jan; 86(1):130-5. PubMed ID: 11857024
[TBL] [Abstract][Full Text] [Related]
9. Comparative effects of new generation oxazaphosphorines on the size and viability of human acute myeloblastic leukemia cells.
Mazur L; Opydo-Chanek M; Wojcieszek K; Stojak M; Niemeyer U
Folia Biol (Krakow); 2012; 60(1-2):35-40. PubMed ID: 22428304
[TBL] [Abstract][Full Text] [Related]
10. Oxazaphosphorines combined with immune checkpoint blockers: dose-dependent tuning between immune and cytotoxic effects.
Delahousse J; Skarbek C; Desbois M; Perfettini JL; Chaput N; Paci A
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32784216
[TBL] [Abstract][Full Text] [Related]
11. Metabolism and transport of oxazaphosphorines and the clinical implications.
Zhang J; Tian Q; Yung Chan S; Chuen Li S; Zhou S; Duan W; Zhu YZ
Drug Metab Rev; 2005; 37(4):611-703. PubMed ID: 16393888
[TBL] [Abstract][Full Text] [Related]
12. Ex vivo responsiveness of head and neck squamous cell carcinoma to glufosfamide, a novel alkylating agent.
Dollner R; Dietz A; Kopun M; Helbig M; Wallner F; Granzow C
Anticancer Res; 2004; 24(5A):2947-51. PubMed ID: 15517901
[TBL] [Abstract][Full Text] [Related]
13. Glufosfamide: beta-D-Glc-IPM, D 19575.
Drugs R D; 2005; 6(1):49-52. PubMed ID: 15801867
[TBL] [Abstract][Full Text] [Related]
14. Insights into oxazaphosphorine resistance and possible approaches to its circumvention.
Zhang J; Tian Q; Chan SY; Duan W; Zhou S
Drug Resist Updat; 2005 Oct; 8(5):271-97. PubMed ID: 16154799
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of halogen analogs of phosphoramide, isophosphoramide, and triphosphoramide mustards, the cytotoxic metabolites of cyclophosphamide, ifosfamide, and trofosfamide.
Struck RF; Schmid SM; Waud WR
Cancer Chemother Pharmacol; 1994; 34(3):191-6. PubMed ID: 8004750
[TBL] [Abstract][Full Text] [Related]
16. Preactivated oxazaphosphorines designed for isophosphoramide mustard delivery as bulk form or nanoassemblies: synthesis and proof of concept.
Skarbek C; Lesueur LL; Chapuis H; Deroussent A; Pioche Durieu C; Daville A; Caron J; Rivard M; Martens T; Bertrand JR; Le Cam E; Vassal G; Couvreur P; Desmaele D; Paci A
J Med Chem; 2015 Jan; 58(2):705-17. PubMed ID: 25494842
[TBL] [Abstract][Full Text] [Related]
17. Intrinsic cellular resistance to oxazaphosphorines exhibited by a human colon carcinoma cell line expressing relatively large amounts of a class-3 aldehyde dehydrogenase.
Rekha GK; Sreerama L; Sladek NE
Biochem Pharmacol; 1994 Nov; 48(10):1943-52. PubMed ID: 7986206
[TBL] [Abstract][Full Text] [Related]
18. Aldehyde dehydrogenase-mediated cellular relative insensitivity to the oxazaphosphorines.
Sládek NE
Curr Pharm Des; 1999 Aug; 5(8):607-25. PubMed ID: 10469894
[TBL] [Abstract][Full Text] [Related]
19. An overview of cyclophosphamide and ifosfamide pharmacology.
Fleming RA
Pharmacotherapy; 1997; 17(5 Pt 2):146S-154S. PubMed ID: 9322882
[TBL] [Abstract][Full Text] [Related]
20. Release of a votile factor from solutions of oxazaphosphorines which damage normal and malignant cells.
Blomgren H; Hallström M
Methods Find Exp Clin Pharmacol; 1989 Jun; 11(6):391-7. PubMed ID: 2747340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
